Previous close | 1.0100 |
Open | 1.0300 |
Bid | 1.0000 x 500 |
Ask | 1.0300 x 100 |
Day's range | 1.0099 - 1.0300 |
52-week range | 0.8800 - 3.3900 |
Volume | |
Avg. volume | 401,760 |
Market cap | 77.682M |
Beta (5Y monthly) | 1.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3000 |
Earnings date | 03 May 2024 - 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.83 |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript March 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2023 Conference Call. All participants […]
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment will be reviewed by the Paul Ehrlich Institute (PEI; Germany's regulatory